SEATTLE, Oct. 19, 2017 -- Trupanion, Inc. (Nasdaq:TRUP), a leading provider of medical insurance for cats and dogs, announced today it will report financial results for its 2017 third quarter after the market closes on Thursday, November 2, 2017. The company will host a conference call that day beginning shortly after 1:30 p.m. PT / 4:30 p.m. ET.
A live webcast will be available on Trupanion's Investor Relations site under Investor Events at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call.
Participants can access the conference call by dialing 1-877-407-0784 (United States) or 1-201-689-8560 (International). A telephonic replay of the call will also be available, one hour after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 13671520.
About Trupanion:
Trupanion is a leading provider of medical insurance for cats and dogs throughout the United States and Canada. For almost two decades, Trupanion has given pet owners peace of mind so they can focus on their pet’s recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance. Trupanion is listed on the Nasdaq Stock Exchange under the symbol TRUP. The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. For more information please visit Trupanion.com.
Contacts:
Investors:
Laura Bainbridge, Addo Investor Relations
310.829.5400
[email protected]
Media:
Scott Janzen, Trupanion Director of Communications
888.612.1138 ext 3450
[email protected]


Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 



